Avivagen (VIV) Stock Price, News & Analysis

Company Overview

Avivagen Inc. focuses on developing and commercializing products for livestock feeds that support immune function and help animals to achieve their growth and productivity. The company offers OxC-beta Livestock, a premix for inclusion in livestock feeds; Vivamune health chews for dogs; Dr. Tobias dog chews; and Dr. Tobias Beta blend for the human immune system. It serves in Canada, Mexico, Brazil, the Philippines, Taiwan, and Thailand. Avivagen Inc. was incorporated in 2005 and is headquartered in Ottawa, Canada.

Key Stats

• Today's Range: C$0.01 to C$0.01
• 50-Day Range: C$0.01 to C$0.01
• 52-Week Range: C$0.01 to C$0.08
• Volume: 2,820 shs
• Average Volume: 49,827 shs
• Market Capitalization: C$388,450.00
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

VIV Stock Analysis - Frequently Asked Questions

How have VIV shares performed this year?

Avivagen's stock was trading at C$0.01 at the beginning of the year. Since then, VIV shares have increased by 0.0% and is now trading at C$0.01.
View the best growth stocks for 2025 here.

How do I buy shares of Avivagen?

Shares of VIV stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

What other stocks do shareholders of Avivagen own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Avivagen investors own include AtkinsRéalis (SNCAF) and ProMetic Life Sciences (PLI).

Industry, Sector and Symbol

• Stock Exchange: CVE
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: Communication
• Current Symbol: CVE:VIV
• CUSIP: N/A
• CIK: N/A
• Web: www.avivagen.com
• Phone: 613-949-8164
• Fax: N/A
• Employees: 34,000
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): C($0.06)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: C$-4,640,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -193.44%

Debt

• Debt-to-Equity Ratio: 2,402.32
• Current Ratio: 0.03
• Quick Ratio: 0.30

Sales & Book Value

• Annual Sales: C$403,780.00
• Price / Sales: 0.96
• Cash Flow: C$0.00 per share
• Price / Cash Flow: 12.14
• Book Value: C($0.12) per share
• Price / Book: -0.04

Miscellaneous

• Outstanding Shares: 77,690,000
• Free Float: N/A
• Market Cap: C$388,450.00
• Optionable: Not Optionable
• Beta: 1.06